MSD - Merck & Co.: latest news - GoINPHARMA
Saturday, 15 December 2018 - 5:57

MSD – Merck & Co.

New approval for Merck & Co.’s Keytruda in Europe

Merck & Co.’s immunotherapy Keytruda keeps winning approvals for new indications. Indeed, it was yesterday approved in Europe, in combination with chemotherapy, for non-small-cell lung cancer (NSCLC). Keytruda is the first inhibitor of  PD-1 receptors to be approved for NSCLC, both…

Merck & Co’s Keytruda obtains approval for NSCLC

Merck & Co.’s immunotherapy Keytruda has received the green light as a first-line treatment, in combination with chemotherapy, for metastatic non-squamous, non-small-cell lung cancer. The approval reflects the positive results from the Phase III KEYNOTE-189 clinical trial, testing the combination…

Merck & Co. could try to acquire Elanco (13.5bn)

Rumors on Merck & Co. targeting Eli Lilly’s Animal Health division Elanco are swirling. Eli Lilly last autumn announced it was planning to sell the asset, valued approximately $13.5bn by analysts.  Merck is already committed in the sector with Merck…

Recent progress in oncology

The FT has published today, on the occasion of the ASCO congress opening, a complex report about recent medicine progress in the fight against cancer. The area with most research activity and trials is immunotherapy, which generated sales of $3.2bn…

Wacker acquisisce un sito per prodotti biofarmaceutici nel Lussenburgo

Bristol-Myers Squibb today reported, before Wall Street opened, detailed results from the Phase III CheckMate-227 clinical trial, testing Opdivo (nivolumab) low-dose 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg in patients with non-small cell lung cancer (NSCLC). The results show that…

Why Merck & Co. makes serious bet on Keytruda

The US-based group Merck & Co. is largely focusing on its blockbuster Keytruda, an immunotherapy launched in Q4 2014 that has delivered approximately $5bn revenues since then, $3.8bn of which in 2017, that is as much as 9% of the…

Analyzing the strategy by Ken Frazier, Merck & Co CEO

The weekly magazine The Economist has published in its latest issue an analysis of the strategy developed over the last ten years by the pharmaceutical group Merck & Co.. The CEO Ken Frazier has been leading the group since 2011,…

Merck & Co. back in the game: Viralytics acquired for €289m

Many analysts were wondering how Merck & Co. would react to the new agreements reached by its competitor Bristol-Myers Squibb, strengthening its presence in the immunotherapy business. Therefore, there is no wonder Merck & Co has announced today the acquisition…

Gilead wins appeal against Merck & Co. and saves $2.54bn

A judge in the federal court in Delaware has ruled in favor of Gilead in an appeal trial concerning patent issues against Merck & Co.. Specifically, the judge has held invalid Merck & Co.’s patent protecting a hepatitis C treatment,…

Germany-based Aicuris obtains FDA approval for antiviral

Aicuris is a young pharmaceutical company, established in 2006 as a spin-off of Bayer, headquartered in Wuppertal (Germany), exclusively focusing on developing novel antiviral and antibacterial agents for the treatment of severe infectious diseases. The company this week has reached…

FDA approves Merck & Co.’s Previmis

Merck & Co. has announced that FDA has approved Previmis (letermovir) once daily (for oral use and injection for intravenous infusion). The product is indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult patients who have to undergo…

New antibiotic therapies: what future?

The state of the art of new substances against bacterial infections has been checked at the IDWeek 2017, organized by the Infectious Disease Society of America (IDSA). One of the drugs recently approved by the FDA is the fixed-dose combination…

New strategic move by BMS: collaboration with Infinity Pharmaceuticals expanded

Bristol-Myers Squibb and Cambridge, US-based biotech company Infinity Pharmaceuticals announced they have expanded the cooperation agreement aimed at evaluating Infinity’s IPI-549 in combination with Opdivo (nivolumab) to include patients with triple negative breast cancer (TNBC). TNBC has shown resistance to…

Merck & Co. acquires Germany-based Rigontec for €464m

Merck & Co. announced today, before Wall Street opening, that it has acquired the German biotech Rigontec for €115m, plus an additional  €349m upon achievement of precise milestones – i.e. approvals and future sales volumes. Rigontec is based in Munich…

An analysis of Merck & Co.

The Wall Street Journal published today a long article analyzing the US-based pharmaceutical giant Merck & Co. Thanks to the company’s size, Merck is considered a relatively safe investment, with growth rates not comparable to those of smaller biotech companies,…

Merck & Co. acquires vaccine facility in Austria

US-based MSD Animal Health acquired from Shire a vaccine production site in Krems, Austria. The facility was opened in 2002 and will increase Merck’s vaccine output. The parties did not provide the financial details of the transaction. (Sources: Merck &…

The strategy to defend blockbusters from biosimilars

Merck and Samsung Bioepis yesterday started selling in the US their biosimilar to Johnson & Johnson’s blockbuster Remicade, with sales of $21bn in 2016. This is the second biosimilar to Remicade: the first was launched in 2016 at a price…